For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 6,914 | 9,583 | 18,119* | 16,242 |
| General and administrative | 4,801 | 5,016 | 6,275* | 5,706 |
| Restructuring and impairment charges | 0 | 0 | 368* | - |
| Total operating expenses | 11,715 | 14,599 | 24,761 | 21,948 |
| Loss from operations | -11,715 | -14,599 | -24,761* | -21,948 |
| Interest income | 1,026 | 1,197 | 2,348* | 2,038 |
| Interest expense | - | 302 | 384* | 403 |
| Other expenses | 538 | - | - | - |
| Net loss | -11,227 | -13,704 | -22,797 | -20,313 |
| Basic EPS | -1.53 | -1.87 | -3.13 | -2.78 |
| Diluted EPS | -1.53 | -1.87 | -3.13 | -2.78 |
| Basic Average Shares | 7,323,106 | 7,311,032 | 7,284,268 | 7,296,222 |
| Diluted Average Shares | 7,323,106 | 7,311,032 | 7,284,268 | 7,296,222 |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)